Question 1

What is Biogen's P/B ratio?

Accepted Answer

Biogen (BIIB) P/B ratio is 1.6× as of June 5, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for Biogen?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For Biogen specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Biogen's P/B ratio high or low?

Accepted Answer

Biogen's P/B ratio of 1.6× is below its own 5-year average of 2.4× and below the sector median of 3.4×. That places the current reading at the 30th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Biogen's historical P/B ratio range?

Accepted Answer

In the available daily series, Biogen (BIIB) P/B ratio has ranged from a low of 0.0× in 2010 to a high of 28.1× in 2001. The 5-year average is 2.4× and the 5-year median is 2.5×.

Question 7

What was Biogen's P/B ratio in 2025?

Accepted Answer

Biogen (BIIB) P/B ratio at the end of 2025 was 1.4×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does Biogen's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$25.82B	$18.26B	1.4×	+0.1×	Dec 31, 2025
2024	$22.28B	$16.72B	1.3×	-1.2×	Dec 31, 2024
2023	$37.50B	$14.80B	2.5×	-0.4×	Dec 31, 2023
2022	$39.90B	$13.40B	3.0×	-0.3×	Dec 31, 2022
2021	$35.24B	$10.90B	3.2×	-0.3×	Dec 31, 2021
2020	$37.63B	$10.70B	3.5×	-0.4×	Dec 31, 2020
2019	$52.76B	$13.34B	4.0×	-0.7×	Dec 31, 2019
2018	$60.12B	$13.04B	4.6×	-0.7×	Dec 31, 2018
2017	$67.38B	$12.61B	5.3×	+0.3×	Dec 31, 2017
2016	$61.42B	$12.14B	5.1×	-2.1×	Dec 31, 2016
2015	$67.52B	$9.37B	7.2×	-0.2×	Dec 31, 2015
2014	$79.93B	$10.81B	7.4×	-0.3×	Dec 31, 2014
2013	$66.06B	$8.62B	7.7×	+2.7×	Dec 31, 2013
2012	$34.63B	$6.96B	5.0×	+0.8×	Dec 31, 2012
2011	$26.74B	$6.43B	4.2×	+1.2×	Dec 31, 2011
2010	$16.19B	$5.40B	3.0×	+0.7×	Dec 31, 2010
2009	$14.44B	$6.22B	2.3×	-0.0×	Dec 31, 2009
2008	$13.70B	$5.81B	2.4×	-0.7×	Dec 31, 2008
2007	$16.86B	$5.53B	3.0×	+0.7×	Dec 31, 2007
2006	$16.74B	$7.15B	2.3×	+0.1×	Dec 31, 2006
2005	$15.38B	$6.91B	2.2×	-1.0×	Dec 31, 2005
2004	$22.33B	$6.83B	3.3×	+1.5×	Dec 31, 2004
2003	$12.25B	$7.05B	1.7×	-6.4×	Dec 31, 2003
2002	$12.94B	$1.60B	8.1×	-20.0×	Dec 31, 2002
2001	$26.88B	$956.48M	28.1×	—	Dec 31, 2001


Align Technology (ALGN)	3.0×
Quest Diagnostics (DGX)	2.9×
Moderna (MRNA)	2.7×
Charles River (CRL)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Danaher (DHR)	2.4×
UnitedHealth Group (UNH)	2.4×
Solventum (SOLV)	2.3×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Molina Healthcare (MOH)	1.7×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Elevance Health (ELV)	1.5×
Universal Health Services (UHS)	1.5×
Baxter International (BAX)	1.4×
Revvity (RVTY)	1.4×
Zimmer Biomet Holdings (ZBH)	1.2×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Centene (CNC)	0.8×

P/B Ratio for Biogen (BIIB)

P/B Ratio daily chart for Biogen (BIIB)

Historical P/B Ratio for Biogen (BIIB) from 2001 to 2025

About P/B Ratio at Biogen (BIIB)

Biogen P/B Ratio by Year

Biogen P/B Ratio 2025: 1.4×

Biogen P/B Ratio 2024: 1.3×

Biogen P/B Ratio 2023: 2.5×

Biogen P/B Ratio 2022: 3.0×

Biogen P/B Ratio 2021: 3.2×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

Biogen (BIIB) Key Financials

P/B Ratio daily chart for Biogen (BIIB)

Historical P/B Ratio for Biogen (BIIB) from 2001 to 2025

About P/B Ratio at Biogen (BIIB)

Biogen P/B Ratio by Year

Biogen P/B Ratio 2025: 1.4×

Biogen P/B Ratio 2024: 1.3×

Biogen P/B Ratio 2023: 2.5×

Biogen P/B Ratio 2022: 3.0×

Biogen P/B Ratio 2021: 3.2×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

+What is Biogen's P/B ratio?

+How is the P/B ratio calculated?

+What is the P/B ratio?

+What is a good P/B ratio for Biogen?

+Is Biogen's P/B ratio high or low?

+What is Biogen's historical P/B ratio range?

+What was Biogen's P/B ratio in 2025?

+Why does Biogen's P/B ratio change over time?

Biogen (BIIB) Key Financials